Skip to main content
ORGANOIDSCIENCES LTD. logo

ORGANOIDSCIENCES LTD. — Investor Relations & Filings

Ticker · 476040 ISIN · KR7476040001 KO Professional, scientific and technical activities
Open in API
Filings indexed 53 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 476040

About ORGANOIDSCIENCES LTD.

https://organoidrx.com/en/

ORGANOIDSCIENCES LTD. is a biotechnology company specializing in organoid-based technologies for drug development and regenerative medicine. The company develops next-generation cell therapies and treatments for incurable diseases by creating three-dimensional cell cultures that replicate the structure and function of human organs. Its core offerings include an Organoid-Based Regenerative Therapeutics Platform to overcome the limitations of conventional therapies and an evaluation platform for assessing drug efficacy and toxicity, providing an alternative to animal models. Additionally, the company has developed the Polaris Platform for evaluating immunotherapy sensitivity. ORGANOIDSCIENCES aims to provide innovative solutions for precise and proactive care, shifting the paradigm in the therapeutics market.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 90% confidence The document is clearly titled “분기보고서” covering the period 2026-01-01 to 2026-03-31 (the first quarter of fiscal 2026). It runs over 150,000 characters, contains substantive narrative and detailed financial statements (sales by segment, asset schedules, R&D costs, etc.), and is not merely an announcement or a link to a report. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-15 Korean
증권발행결과(자율공시) (제3자배정유상증자)
Regulatory Filings
2026-05-07 Korean
증권발행결과(자율공시) (제1회차CB)
Regulatory Filings
2026-05-07 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 88% confidence The document is a Korean "주요사항보고서(유상증자결정)" (Major Event Report on resolution of a paid-in capital increase) filed with the Financial Services Commission/KRX. It contains detailed terms of a third-party allotment of new shares: types and numbers of shares, issue price, allotment method, conversion rights, call options, board resolutions, etc. This is an announcement of a share issuance and capital change rather than a full annual/interim report or earnings release. It fits the “Share Issue/Capital Change” category (SHA).
2026-04-30 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 94% confidence The document is a Korean ‘‘주요사항보고서’’ (Material Event Report) detailing the decision to issue 24 billion KRW of convertible bonds including full financing terms, put/call options, conversion price adjustment mechanisms, and list of investors. It is not a quarterly/annual report or regulatory publication notice, but a primary disclosure of a new debt‐financing/capital structure transaction. This fits the Capital/Financing Update category (CAP).
2026-04-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 98% confidence The document is a Korean "주식등의 대량보유상황보고서(일반)" under the Capital Markets Act, disclosing the beneficial owner’s shareholding levels, changes in ownership and voting rights. This is a regulatory notification of significant shareholding (threshold crossing) rather than a general earnings release or management report. Therefore it matches the Major Shareholding Notification category (Code: MRQ).
2026-04-06 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.